News

Article

Early-onset atopic dermatitis linked to higher risk of pediatric uveitis

Author(s):

Key Takeaways

  • Children with early-onset atopic dermatitis have a higher risk of developing pediatric uveitis compared to matched controls.
  • The study found increased uveitis risk in patients untreated with dupilumab and those without autoimmune conditions.
SHOW MORE

A study found that children with early-onset atopic dermatitis have a higher risk of developing uveitis and should be closely monitored for its onset.

(Image Credit: AdobeStock/Юля Шевцова)

(Image Credit: AdobeStock/Юля Шевцова)

Taiwanese investigators found in their cohort study that children with early-onset atopic dermatitis had an increased risk of developing uveitis and should be carefully observed to identify that onset.1 The study was led by Yung-Yu Chu, MD, from the Department of Ophthalmology, Chi Mei Medical Center, Tainan, Taiwan.

The researchers retrospectively evaluated the electronic health records of US patients in TriNetX, a collaborative research network, to identify patients with early-onset atopic dermatitis. The study also included matched controls without atopic dermatitis and excluded patients with uveitis before atopic dermatitis was diagnosis. The primary outcome was the hazard ratio (HR) for developing pediatric uveitis in the atopic dermatitis cohort compared with the matched controls, the authors explained.

The search of the health records identified 114,889 patients in the atopic dermatitis and control cohorts; the respective mean patient ages were 0.5 year and 0.6 years.

The results showed that 94 patients with atopic dermatitis developed pediatric uveitis compared with 58 controls (HR, 1.92 [95% confidence interval [CI], 1.38-2.66]).

The results also found that patients in the atopic dermatitis cohort who were not treated with dupilumab (Dupixent, Sanofi and Regeneron Pharmaceuticals), which is approved to treat the disease (89 of 113, 284 [0.08%] vs 59 of 113, 284 [0.05%]; HR, 1.77 [95% CI, 1.27-2.46]), and patients without autoimmune conditions (80 of 114, 425 [0.07%] vs 61 of 114,425 [0.05%]; HR, 1.52 [95% CI, 1.09-2.12]) also had an increased risk of developing uveitis.

The severity of atopic dermatitis also was an important factor, in that those with severe diseasehad a higher risk of developing pediatric uveitis compared with those with nonsevereatopic dermatitis (12 of 3,004 [0.40%] vs 97 of 126,482 [0.08%]; HR, 3.64 [95% CI, 2.00-6.66]), Dr. Chu and colleagues reported.

Investigators concluded, “This cohort study of children with early-onset AD found an elevated risk of pediatric uveitis compared with matched controls, independent of autoimmune conditions or dupilumab use. These findings support the potential need to consider ophthalmologic monitoring in children with early-onset AD to try to detect and subsequently manage uveitis if it develops.”

They also advised that the relationship between atopic dermatitis and pediatric uveitis may be underexplored and, therefore, warrants large-scale, multicenter studies.

Reference
  1. Chu Y-Y, Sung C-H, Lin Y-S, et al. Risk of developing pediatric uveitis among patients with early-onset atopic dermatitis.JAMA Ophthalmol.Published online April 3, 2025. doi:10.1001/jamaophthalmol.2025.0366

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
© 2025 MJH Life Sciences

All rights reserved.